Prof. Chen is a world-leading molecular imaging/therapy and nanomedicine researcher. He has published over 1000 papers (total citations > 130,000, H Index >190)

He is the founding editor of journal Theranostics (current IF 12.4), and sits on the editorial board of a number of prestigious journals such as Acc Chem Res, ACS Nano, Bioconjug Chem, Bioeng Transl Med, J Nucl Med, Eur J Nucl Med Mol Imaging, etc.

Prof. Chen’s achievements have been well recognized as illustrated by him receiving a number of prestigious awards, including the JNB Trailblazer Award (2023), Michael J. Welch Award from the Society of Nuclear Medicine and Molecular Imaging (2019), the ACS Bioconjugate Chemistry Lectureship Award (2016), the National Institutes of Health (NIH) Director’s Award (2014), and National Institute of Biomedical Imaging and Bioengineering (NIBIB) Mentor Award (2012). In particular, the Michael J. Welch, PhD Award represents the highest honor bestowed on recognizing individuals who have made an outstanding contribution to the field of radiopharmaceutical sciences, have been involved in mentoring students, postdoctoral fellows and junior faculty, and have been involved in community service to the field of radiopharmaceutical chemistry and molecular imaging.

Prof. Chen is also a Fellow of the American Institute for Medical and Biological Engineering (AIMBE), and a fellow of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

• Advanced Materials Hall of Fame, 2023
• JBN Trailblazer Award, 2023
• Society of Nuclear Medicine and Molecular Imaging (SNMMI) Fellow, 2020
• Michael J. Welch, PhD Award, SNMMI, 2019
• ACS Nano, Bioconjug Chem, and Mol Pharm Selected Highly Prolific Authors, 2017
• American Institute for Medical and Biological Engineering (AIMBE) Fellow, 2017
• Clarivate Analytics highly cited researcher, 2017/2018/2019/2020
• ACS Bioconjugate Chemistry Lectureship Award, 2016
• NIH Director’s Award, 2014
• NIBIB Mentor Award, 2012

Prof. Chen is a world-leading molecular imaging/therapy and nanomedicine researcher. He has published over 1000 papers (total citations > 130,000, H Index >190)

He is the founding editor of journal Theranostics (current IF 12.4), and sits on the editorial board of a number of prestigious journals such as Acc Chem Res, ACS Nano, Bioconjug Chem, Bioeng Transl Med, J Nucl Med, Eur J Nucl Med Mol Imaging, etc.

Prof. Chen’s achievements have been well recognized as illustrated by him receiving a number of prestigious awards, including the JNB Trailblazer Award (2023), Michael J. Welch Award from the Society of Nuclear Medicine and Molecular Imaging (2019), the ACS Bioconjugate Chemistry Lectureship Award (2016), the National Institutes of Health (NIH) Director’s Award (2014), and National Institute of Biomedical Imaging and Bioengineering (NIBIB) Mentor Award (2012). In particular, the Michael J. Welch, PhD Award represents the highest honor bestowed on recognizing individuals who have made an outstanding contribution to the field of radiopharmaceutical sciences, have been involved in mentoring students, postdoctoral fellows and junior faculty, and have been involved in community service to the field of radiopharmaceutical chemistry and molecular imaging.

Prof. Chen is also a Fellow of the American Institute for Medical and Biological Engineering (AIMBE), and a fellow of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

• Academic CV

• Feng Z, Zhang X, Zhou J, Li Q, Chu L, Di G, Xu Z, Chen Q, Wang M, Jiang X, Xia H, Chen X.

  An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma.

  Nat Cancer. 2023 Oct 16. doi: 10.1038/s43018-023-00650-8.

• Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W, Pang Y, Guo W, Sun L, Wu H, Xu P, Su B, Zhang J, Chen X, Chen H.

  Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer.
  First-in-Human, Dose-Escalation Study.

  Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983.

• Cao F, Jin L, Zhang C, Gao Y, Qian Z, Wen H, Yang S, Ye Z, Hong L, Yang H, Tong Z, Cheng L, Ding Y, Wang W, Yu G, Mao Z, Chen X.

  Engineering Clinically Relevant Probiotics with Switchable “nano-promoter” and “nano-effector” for Precision Tumor Therapy.

  Adv Mater. 2023 Oct 3:e2304257. doi: 10.1002/adma.202304257.

• Zhang J, Zhao T, Jakobsson V, Chen X

  Clinical translation of radiotheranostics for precision oncology

  Nat Rev Bioeng. 2023; 1: 612–614. doi: 10.1038/s44222-023-00106-9

• Shi C, Zhang Q, Yao Y, Zeng F, Du C, Nijiati S, Wen X, Zhang X, Yang H, Chen H, Guo Z, Zhang X, Gao J, Guo W, Chen X, Zhou Z.

  Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics.

  Nat Nanotechnol. 2023 Jan;18(1):86-97. doi: 10.1038/s41565-022-01261-7.

• Cao F, Jin L, Gao Y, Ding Y, Wen H, Qian Z, Zhang C, Hong L, Yang H, Zhang J, Tong Z, Wang W, Chen X, Mao Z.

  Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis.

  Nat Nanotechnol. 2023 Jun;18(6):617-627. doi: 10.1038/s41565-023-01346-x.

• Liu C, Liu X, Xiang X, Pang X, Chen S, Zhang Y, Ren E, Zhang L, Liu X, Lv P, Wang X, Luo W, Xia N, Chen X, Liu G.

  A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy.

  Nat Nanotechnol. 2022 May;17(5):531-540. doi: 10.1038/s41565-022-01098-0.

• Bhatia SN, Chen X, Dobrovolskaia MA, Lammers T.

  Cancer nanomedicine.

  Nat Rev Cancer. 2022 Oct;22(10):550-556. doi: 10.1038/s41568-022-00496-9.

• Li L, Zou J, Dai Y, Fan W, Niu G, Yang Z, Chen X.

  Burst release of encapsulated annexin A5 in tumours boosts cytotoxic T-cell responses by blocking the phagocytosis of apoptotic cells.

  Nat Biomed Eng. 2020 Nov;4(11):1102-1116. doi: 10.1038/s41551-020-0599-5.

• Chen H, Zhang W, Zhu G, Xie J, Chen X.

  Rethinking cancer nanotheranostics.

  Nat Rev Mater. 2017;2:17024. doi: 10.1038/natrevmats.2017.24.